Evidence map›Paper›PMID 28809098›Full record

ArticleACS applied materials & interfaces2017

Interfacially Engineered Pyridinium Pseudogemini Surfactants as Versatile and Efficient Supramolecular Delivery Systems for DNA, siRNA, and mRNA.

Uttam Satyal, Bogdan Draghici, Lisa L Dragic, Qiangnan Zhang, Kyle W Norris, Muniswamy Madesh, Eugen Brailoiu, Marc A Ilies

Abstract read
In one paragraph

Article in ACS applied materials & interfaces, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Lipid-based nucleic acid therapeutics with in vivo efficacy.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2023
    Review
  2. Review
  3. Article
  4. Article
  5. Nanoscale platforms for messenger RNA delivery.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2019
    Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Uttam SatyalDepartment of Pharmaceutical Sciences and Moulder Center of Drug Discovery Research, Temple University School of Pharmacy , Philadelphia, Pennsylvania 19140, United States.
Bogdan DraghiciDepartment of Pharmaceutical Sciences and Moulder Center of Drug Discovery Research, Temple University School of Pharmacy , Philadelphia, Pennsylvania 19140, United States.
Lisa L DragicDepartment of Pharmaceutical Sciences and Moulder Center of Drug Discovery Research, Temple University School of Pharmacy , Philadelphia, Pennsylvania 19140, United States.
Qiangnan ZhangDepartment of Pharmaceutical Sciences and Moulder Center of Drug Discovery Research, Temple University School of Pharmacy , Philadelphia, Pennsylvania 19140, United States.
Kyle W NorrisDepartment of Pharmaceutical Sciences and Moulder Center of Drug Discovery Research, Temple University School of Pharmacy , Philadelphia, Pennsylvania 19140, United States.
Muniswamy Madesh
Eugen Brailoiu
Marc A IliesDepartment of Pharmaceutical Sciences and Moulder Center of Drug Discovery Research, Temple University School of Pharmacy , Philadelphia, Pennsylvania 19140, United States.ORCID http://orcid.org/0000-0003-0694-411X

Funding

Coordination of Pathophysiologic Endothelial Cell Signaling by ROSR01HL086699 · NHLBI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI MUNISWAMY, MADESH · 2008 to 2018
$4.3M
Spectral revelations of mitochondrial Ca2+ flux interactomeR01GM109882 · NIGMS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI MUNISWAMY, MADESH · 2014 to 2022
$3.3M
Inhibition of MCUR1-MCU mediated mitochondrial Ca2+ uptake prevents I/R injuryR01HL119306 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI MUNISWAMY, MADESH · 2014 to 2017
$1.6M
Multiphoton upgrade of confocal microscope for live organ and tissue imagingS10RR022511 · NCRR · UNIVERSITY OF PENNSYLVANIA · PI MUNISWAMY, MADESH · 2007 to 2007
$500k
NCRR NIH HHS S10 RR022511NHLBI NIH HHS R01 HL086699NHLBI NIH HHS R01 HL119306NIGMS NIH HHS R01 GM109882
6 · The paper itself

Abstract

This article presents the synthesis, self-assembly, and biological activity as transfection agents for pDNA, siRNA, and mRNA of novel pyridinium pseudogemini surfactants, interfacially engineered from the most efficient gemini surfactants and lipids generated in our amphiphile research program. Formulation of novel amphiphiles in water revealed supramolecular properties very similar to those of gemini surfactants, despite their lipidlike charge/mass ratio. This dual character was found also to enhance endosomal escape and significantly increase the transfection efficiency. We were also successful in identifying the parameters governing the efficient delivery of pDNA, siRNA, and mRNA, drawing valuable structure-activity and structure-property relationships for each nucleic acid type, and establishing DNA/siRNA/mRNA comparisons. Several supramolecular complexes identified in this study proved to be extremely efficient nucleic acid delivery systems, displaying excellent serum stability and tissue penetration in three-dimensional organoids.

Indexed as

DNARNA, MessengerRNA, Small InterferingSurface-Active AgentsTransfectionDNARNA, MessengerRNA, Small InterferingSurface-Active AgentsamphiphileDNAmRNApyridiniumsiRNAtransfection

Identifiers

PMID28809098
PMCPMC7774514

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.